17-hydroxyjolkinolide b has been researched along with Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kinghorn, AD; Ren, Y | 1 |
| Gu, Y; Ma, X; Qin, G; Shen, S; Wang, H; Wang, Y; Yan, S; Yu, Q; Zhu, H | 1 |
2 other study(ies) available for 17-hydroxyjolkinolide b and Neoplasms
| Article | Year |
|---|---|
Development of Potential Antitumor Agents from the Scaffolds of Plant-Derived Terpenoid Lactones.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Biological Products; Diterpenes; Humans; Neoplasms; Sesquiterpenes; Structure-Activity Relationship; Triterpenes | 2020 |
17-hydroxy-jolkinolide B inhibits signal transducers and activators of transcription 3 signaling by covalently cross-linking Janus kinases and induces apoptosis of human cancer cells.
Topics: Apoptosis; Cell Line, Tumor; Diterpenes; Drugs, Chinese Herbal; Euphorbia; Humans; Interleukin-6; Janus Kinase 2; Janus Kinases; Neoplasms; Signal Transduction; STAT3 Transcription Factor; Tyrphostins | 2009 |